Celea Therapeutics doses first patient in phase 3 IPF drug trial

July 13, 2026 2:00 AM

Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found